Adaptive Biotechnologies (NASDAQ: ADPT) recently received a number of ratings updates from brokerages and research firms:
- 8/4/2026 – Adaptive Biotechnologies had its price target raised by Piper Sandler from $20.00 to $27.50. They now have an “overweight” rating on the stock.
- 7/30/2026 – Adaptive Biotechnologies had its price target raised by Guggenheim from $22.00 to $25.00. They now have a “buy” rating on the stock.
- 7/30/2026 – Adaptive Biotechnologies had its price target raised by Morgan Stanley from $20.00 to $22.00. They now have an “equal weight” rating on the stock.
- 7/30/2026 – Adaptive Biotechnologies had its price target raised by TD Cowen from $25.00 to $28.00. They now have a “buy” rating on the stock.
- 7/30/2026 – Adaptive Biotechnologies had its price target raised by BTIG Research from $24.00 to $25.00. They now have a “buy” rating on the stock.
- 7/17/2026 – Adaptive Biotechnologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/15/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by TD Cowen.
- 7/9/2026 – Adaptive Biotechnologies had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
- 6/29/2026 – Adaptive Biotechnologies had its price target raised by Guggenheim from $21.00 to $22.00. They now have a “buy” rating on the stock.
- 6/17/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by BTIG Research. They now have a $22.00 price target on the stock.
Insider Activity at Adaptive Biotechnologies
In other news, insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the transaction, the insider directly owned 221,278 shares in the company, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80. Following the completion of the sale, the insider directly owned 237,688 shares of the company’s stock, valued at $5,336,095.60. The trade was a 17.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,307,086 shares of company stock valued at $27,859,739. 5.70% of the stock is owned by insiders.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
- Five stocks we like better than Adaptive Biotechnologies
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Adaptive Biotechnologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
